Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Myoung S. Kim, PhD, MBA
Executive Director, Epidemiology,
Medical Affairs, Johnson & Johnson,
New Brunswick, NJ
Executive Director, Epidemiology,
Medical Affairs, Johnson & Johnson,
New Brunswick, NJ
Authored Items
Modeling the Frequency and Costs Associated with Postsurgical Gastrointestinal Adverse Events for Tapentadol IR versus Oxycodone IR
Andrew Paris, MBA
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Chris M. Kozma, PhD
,
Wing Chow, PharmD, MPH
,
Anisha M. Patel, MS
,
Samir H. Mody, PharmD, MBA
,
Myoung S. Kim, PhD, MBA
November/December 2013, Vol 6, No 9
in
Practice Management
Last modified: December 19, 2013